$BLLN News

Last published 5h ago

5h agoBLLN MBX OMDANorwest Announces $4 Billion Global, Multi-Stage FundBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Norwest, a global, multi-stage investment firm, today announced the close of Norwest 18, a $4 billion fund and the largest in the firm's 65-year history, bringing its total capital under management to $18 billion. The fund will support venture and growth equity investments across technology, healthcare, and consumer sectors in the U.S., India, and Israel, build ...
1d agoBLLNUBS Global Healthcare Conference - BILLIONTOONE INCEarnings Call TranscriptsAll right. Good afternoon. I'm Doug Schenkel with UBS, and it's my pleasure to welcome Okazan Ate, co-founder and chief executive officer of Billion to One. Thank you for being here. I appreciate you making the trip. So
1w agoBLLNBillionToOne, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoBLLNBillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue GuidanceGlobeNewswireMENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
2w agoBLLNBillionToOne to Participate in Two Upcoming Investor ConferencesGlobeNewswireMENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
4w agoBLLNBillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireMENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
1mo agoBLLNBillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study FindsGlobeNewswireMENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
2mo agoBLLNWells Fargo 21st Annual Healthcare Conference - BILLIONTOONE INCEarnings Call TranscriptsHi, everyone. We're back here, Life Science Tools and Diagnostics. We have Billion and One, Ozan Ate, CEO and founder. Maybe let's just start 2Q. Revenues grew 64%, volumes 35%, strong gross margins, and you were profita
2mo agoBLLNWells Fargo 21st Annual Healthcare Conference - BILLIONTOONE INCEarnings Call TranscriptsHi, everyone. We're back here, Life Science Tools and Diagnostics. We have Billion and One, Ozan Ate, CEO and founder. Maybe let's just start 2Q. Revenues grew 64%, volumes 35%, strong gross margins, and you were profita
2mo agoBLLNBillionToOne to Participate in the Wells Fargo 21st Annual Healthcare ConferencePR NewswireBillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
2mo agoBLLNBillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of OriginPR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
2mo agoBLLN/C O R R E C T I O N -- BillionToOne/PR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
3mo agoBLLNBillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue GuidanceGlobeNewswireMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
3mo agoBLLNBillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for NorthstarPR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
4mo agoBLLNBillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireMENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
4mo agoBLLNBillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed StudyPR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
5mo agoBLLNBillionToOne, Inc. William Blair 46th Annual Growth Stock Conference - BILLIONTOONE INCEarnings Call TranscriptsHi, everyone. Good afternoon. Thanks for joining us here on the first afternoon of the William Blair Growth Stock Conference. If you don't know me, my name is Andrew Brackman. I'm the equity research analyst covering the
5mo agoBLLNBillionToOne to Participate in the William Blair 46th Annual Growth Stock ConferenceGlobeNewswireMENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
6mo agoBLLNBillionToOne 1Q26 Earnings Call - BILLIONTOONE INCEarnings Call TranscriptsThank you for standing by, and welcome to the Billion to One First Quarter 2026 Earnings Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer
6mo agoBLLNBillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue GuidanceGlobeNewswireMENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
7mo agoBLLNBillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireMENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
7mo agoBLLNBillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, OncologyPR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today ...
8mo agoBLLNBillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue GuidanceGlobeNewswireMENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
8mo agoBLLNBillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026GlobeNewswireMENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
9mo agoBLLNBillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®PR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
9mo agoBLLNBillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal CarePR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
10mo agoBLLNBillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across HealthcarePR NewswireBillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
10mo agoBLLNBillionToOne Provides Guidance for 2026GlobeNewswireMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
10mo agoBLLNBillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital EastPR NewswireBillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...
10mo agoBLLNBillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
11mo agoBLLNBillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee ChairPR NewswireMENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to...
11mo agoBLLNBillionToOne Reports Third Quarter 2025 ResultsGlobeNewswireMENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all,
11mo agoBLLNBillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025GlobeNewswireMENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced
1y agoBLLNBillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireMENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of
1y agoBLLNGunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public OfferingPR NewswireGunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, a leading law firm in technology and life sciences transactions, represented long-time ...
1y agoBLLNBillionToOne Announces Pricing of Upsized Initial Public OfferingGlobeNewswireMENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced
1y agoBLLNBillionToOne Announces Launch of Initial Public Offering RoadshowGlobeNewswireMENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has